The CD38/NPP1/CD73 pathway has been shown to be operative together with the classical pathway in different populations of lymphocytes, as well as in melanoma and myeloma cells, and in different cell subsets of the bone marrow niche in multiple myeloma patients, where ADO production results in tumor-driven immune suppression [121]. Here, CD38 is linked to plasma cell myeloma.